Application 202365
- Type
- ANDA
- Sponsor
- WATSON LABS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | TABLET;ORAL | 50MG;500MG | No | No |
| 002 | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE | TABLET;ORAL | 50MG;1000MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.